Activation of GPR39 With TC-G 1008 Attenuates Neuroinflammation Via SIRT1/PGC-1α/Nrf2 Pathway Post Neonatal Hypoxic-ischemic Injury in Rats

Shucai Xie
Department of Critical Care Medicine, Xiangya Hospital, Central South University
https://orcid.org/0000-0002-2620-3637

Xili Jiang
Department of Radiology, The Second People's Hospital of Hunan Province/Brain Hospital of Hunan

Desislava Met Doycheva
Loma Linda University School of Medicine

Hui Shi
Loma Linda University School of Medicine

Peng Jin
Loma Linda University School of Medicine

Ling Gao
Loma Linda University School of Medicine

Rui Liu
Loma Linda University School of Medicine

Jie Xiao
Loma Linda University School of Medicine

Xiao Hu
Loma Linda University School of Medicine

Jiping Tang
Loma Linda University School of Medicine

Lina Zhang
Department of Critical Care Medicine, Xiangya hospital, Central South University

John H Zhang (johnzhang3910@yahoo.com)
Department of Neurosurgery and Anesthesiology, Loma Linda University Medical Center, Loma Linda, CA 92354, USA
https://orcid.org/0000-0002-4319-4285
Abstract

Background: Hypoxic-ischemic encephalopathy (HIE) is a severe anoxic brain injury that leads to premature mortality or long-term disabilities in infants. Neuroinflammation is a vital contributor to the pathogenic cascade post HIE and a mediator to secondary neuronal death. As a plasma membrane G-protein coupled receptor, GPR39, exhibits anti-inflammatory activity in several diseases. This study aimed to explore the neuroprotective function of GPR39 through inhibition of inflammation post hypoxic-ischemic (HI) injury and to elaborate the contribution of sirtuin 1 (SIRT1) / peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) / nuclear factor, erythroid 2 like 2 (Nrf2) in G protein-coupled receptor 39 (GPR39)-mediated protection.

Methods: A total of 206 10-day old Sprague Dawley rat pups were subjected to HIE or sham surgery. TC-G 1008 was administered intranasally at 1h, 25h, 49h, and 73h post HIE induction. SIRT1 inhibitor EX527, GPR39 CRISPR, and PGC-1α CRISPR were administered to elucidate the underlying mechanisms. Brain infarct area, short-term and long-term neurobehavioral tests, Nissl staining, western blot, and immunofluorescence staining were performed post HIE.

Results: The expression of GPR39 and pathway-related proteins, SIRT1 / PGC-1α and Nrf2 were increased in a time-dependent manner, peaking at 24 h or 48h post HIE. Intranasal administration of TC-G 1008 reduced the percent infarcted area and improved short-term and long-term neurological deficits. Moreover, TC-G 1008 treatment significantly increased the expression of SIRT1, PGC-1α, Nrf2, IL-6, IL-1β, and TNF-α. GPR39 CRISPR EX527 and PGC-1α CRISPR abolished GPR39’s neuroprotective effects post HIE.

Conclusions:

TC-G 1008 attenuated neuroinflammation in part via the SIRT1 / PGC-1α / Nrf2 pathway in a neonatal rat model of HIE. TC-G 1008 may be a novel therapeutic target for treatment post neonatal HIE injury.

Introduction

Hypoxic-ischemic encephalopathy (HIE) is a severe anoxic brain injury that leads to premature mortality or long-term disabilities in newborns, such as cerebral palsy, cognitive deficits, and mental retardation[1-3]. HIE contributed to 23% of neonatal deaths globally and has an incidence of 26 per 1000 live births in developing countries[4, 5]. The established standard of treatment for HIE is therapeutic hypothermia, but it can only provide limited neuroprotection[6]. In recent years, researchers have focused on finding new therapies to improve efficiency, enhance neuroprotection, and reduce side effects. For example, some peptides, activated by severe anoxic injury, might be involved in perinatal HIE’s pathophysiology and could be the potential therapeutic target for HIE.

As one of HIE pathophysiology’s main events, inflammatory responses take place within minutes post HIE injury and mediate secondary neuronal death[7, 8]. The activation of neuroglial cells promotes the release of a large number of pro-inflammatory cytokines and reactive oxygen species (ROS), thereby leading to
neuronal apoptosis. On the other hand, emerging evidence has demonstrated that inflammatory responses also play a beneficial role, and anti-inflammation is also one of the present neuroprotective agents’ main mechanisms. Activated microglia/macrophages can induce phagocytosis and the production of anti-inflammatory cytokines, which inhibits neuroinflammation and protects remaining viable neurons from death[9-12].

G protein-coupled receptor 39 (GPR39), a plasma membrane G-protein coupled receptor, was first cloned and identified in 1997[13]. GPR39 is expressed in the gastrointestinal tract, amygdala, hippocampus, and auditory cortex, and zinc was thought to be a natural ligand of GPR39[14, 15]. Activation of GPR39 and related subsequent signaling cascade has been identified in several cells and shown to regulate a vast array of physiological functions, such as proliferation, differentiation, ion transport and tight junction formation[16]. Moreover, activation of GPR39 has been demonstrated to promote wound healing, ameliorate symptoms of inflammatory bowel diseases, dampen epileptic seizure activity, reduce anxiety-like behaviors and regulate insulin secretion and malignant progression of several cancers[17-24]. Recently, accumulating in vitro evidence demonstrated that GPR39 exhibits anti-inflammatory activity by reducing the expression of pro-inflammatory cytokines (IL-1β, IL-6), enhancing anti-inflammatory cytokines production (IL-10), ameliorating oxidative stress and mitochondrial dysfunction[25-27].

A small amount of literature confirms that GPR39 might play a neuroprotective role in neuronal injury by inhibiting apoptosis and ameliorating endoplasmic reticulum stress[28-30]. However, whether GPR39 activation has protective and anti-inflammatory effects post HIE remains unexplained. In the present study, we hypothesized that GPR39 agonist, TC-G 1008, attenuates inflammation via sirtuin 1 (SIRT1)/PPARG coactivator 1 alpha (PGC-1α)/ nuclear factor, erythroid 2 like 2 (Nrf2), leading to improvement of neurological function in a rat model of neonatal HIE.

**Materials And Methods**

**Animals and model**

In this study, all experimental protocols were approved by the Institutional Animal Care and Use Committee of Loma Linda University. All studies were performed in accordance with the United States Public Health Service’s Policy on Humane Care and Use of Laboratory Animals. Litters of Sprague Dawley rats, containing 12 pups and their mothers, were purchased from Envigo (Livermore, CA). A total of 206 10-day-old (P10) pups with body weights ranging from 16 to 23 g were used in this experimental study (Fig.S1). The animal model used in this study is the Modified Rice Vannucci neonatal hypoxia-ischemia (HI) model[31]. Briefly, 3% isoflurane was used to anesthetize rat pups, and 2.5% isoflurane was used for maintenance during surgery. The upper and lower edges of the isolated common carotid (CCA) artery were ligated with 5-0 silk thread and severed between the ligatures. However, for pups in the sham group we only isolated the CCA. Pups were allowed to recover for an hour on a heated blanket, following which they were placed in an airtight jar partially immersed in a 37°C constant temperature water bath, and
exposed for 2.5 h to a gas mixture of 8% oxygen and 92% nitrogen. Pups in the sham group only got their CCA isolated without ligation and severance, and without undergoing hypoxia exposure.

Experimental design

Experiment 1

To explore the time course expression levels of endogenous GPR39, SIRT1, PGC-1α and Nrf2 post HIE, six time points (6h, 12h, 24h, 48h, 72h, 7d) were selected. The right (ipsilateral) brain samples were separate for protein extraction.

Experiment 2

To assess the neuroprotective effect of TC-G 1008 on pups post HIE, three doses of TC-G 1008 were used. The groups included sham, HIE+vehicle, HIE+TC-G 1008(5mg/kg), HIE+TC-G 1008 (15mg/kg), HIE+TC-G 1008(45mg/kg). TC-G 1008, suspended in 1% Tween in H2O, was administered intranasally at 1 h following HIE. Righting reflex, negative geotaxis tests and body weights were conducted at 48 h post HIE. Rats were then sacrificed and whole brain samples were separated for TTC staining or immunofluorescence staining.

Experiment 3

Long-term effects of TC-G 1008 treatment on neurological function was evaluated by neurobehavioral tests including foot-fault, rotarod test and water maze. Sham group, HIE+vehicle group and HIE+TC-G 1008 group (15mg/kg) were included in the analysis. TC-G 1008 was administered at 1h, 25h, 49h, and 73h post HIE. After the neurobehavioral tests were completed, rats were sacrificed and whole brain samples were removed for Nissl staining.

Experiment 4

To analyze whether GPR39 receptor and signaling pathway-related proteins, SIRT1 and PGC-1α, participate in the underlying mechanism of TC-G 1008- mediated anti-neuroinflammation effects, CRISPR was used to inhibit GPR39 and PGC-1α and EX527 was used to inhibit SIRT1. Rat pups were randomly divided into 8 groups, sham, HIE+vehicle, HIE+TC-G 1008 group, HIE+TC-G 1008+control CRISPR, HIE+TC-G 1008+GPR39 CRISPR, HIE+TC-G 1008+PGC-1α CRISPR, HIE+TC-G 1008+EX527. TC-G 1008 (optimal dose) or DDH2O were administered intranasally at 1 h following HIE induction. GPR39 CRISPR, control CRISPR or PGC-1α CRISPR (1µg/pup) was given intracerebroventricularly at 48 h before HIE induction. EX527 (10 mg/kg) or DMSO was injected intraperitoneally at 1 h before HIE induction. Righting reflex, negative geotaxis tests, TTC staining, body weight, and immunofluorescence staining were conducted at 48h post HIE.

Drug administration
TC-G 1008 (5, 15, 45 mg/kg, Tocris Bioscience, USA) was administered intranasally[32]. A total of 6 μl of TC-G 1008 or DDH₂O was given every 2 min in alternating nares. EX527 (10mg/kg, abcam, USA), or DMSO was injected intraperitoneally at 1 h before HIE. GPR39 CRISPR (Santa Cruz Biotechnology, USA), PGC-1α CRISPR (Santa Cruz Biotechnology, USA), or control CRISPR (Santa Cruz Biotechnology, USA) were given intracerebroventricularly (1.5 mm anterior, 1.5 mm lateral to the Bregma, and 1.7 mm deep on the ipsilateral hemisphere) at 48 h before HIE induction.

**Neurobehavioral tests**

Following the principle of double-blind, neurobehavioral tests were performed by two investigators in an unbiased setup at either 48 h or 4 weeks post HIE. Short-term behavioral tests include righting reflex and negative geotaxis were performed at 48 h post HIE, while long-term behavioral tests rotarod, water maze, and foot-fault were performed at 4 weeks post HIE.

In negative geotaxis test, pups were placed head downward on a 45-degree sloping board. The time from placing pups on the board to when pups rotated their bodies to head upward position was recorded. The maximum testing time was 1 minute. In righting reflex test, the time from a back position that they were initially placed on to pups turning on all fours was recorded.

In foot fault, rats were placed to walk on a horizontal grid floor (square size 20 cm-40 cm with a mesh size of 4 cm²) elevated 1m above ground for 1 min. The number of misplaced forelimbs or hindlimbs were recorded by video equipment (iponhe 6s, USA).

In rotarod test, rats were placed on a rotating, horizontal, constant speed or accelerating rod (Columbus Instruments Rotamex, USA). The duration of rats on the rotarod was recorded by video equipment.

Morris water maze test was used to assess learning, memory, and visual ability on days 24–28 post HIE. A hidden platform was set up by submerging it in a pool of water. Rats were trained to find the platform using visual cues around the room in both cued tests and hidden tests. If the rats could not reach the platform within 1 minute, they would be manually guided to the platform. The probe experiment was scheduled on the 5th day after training and the platform was removed. The length of time it took the rats to reach the platform and the swimming distance of rats were tracked with the Video Tracking System SMART-2000 (San Diego Instruments Inc., USA). Subsequently, the distance, latency, and probe quadrant duration were quantified and analyzed.

**Infarct Area Measurements**

Rat pups were anesthetized and euthanized at 48 h post HIE. Brains were isolated, cut into 2 mm slices and stained with 2% solution of 2,3,5 triphenyltetrazolium chloride (TTC) (Sigma Aldrich, USA). Image J software (NIH) was used to analyze and calculate the infarct area. The percentage of infarct area = [(contralateral hemisphere − nonlesioned ipsilateral hemisphere)/2 × contralateral hemisphere] × 100% [33].
Western Blot

The expression levels of GPR39, SIRT1, PGC-1α and Nrf2 were measured at 0 h, 6 h, 12 h, 24 h, 48 h, 72 h and 7d post HIE by Western blot following the manufacturer’s recommendations[34, 35]. To analyze whether GPR39 receptor and SIRT1/PGC-1α/Nrf2 pathway were involved in the neuroprotective effects of TC-G 1008, the expression levels of GPR39, SIRT1, PGC-1α and Nrf2 and pivotal inflammatory cytokines IL-6, IL-1β, TNF-α were assessed via Western blot. RIPA lysis buffer (Santa Cruz Biotechnology, USA) was used to obtain whole cell lysates. Primary antibodies used were rabbit anti-GPR39 (1:500, Bioss), mouse anti-SIRT1 (1:2000, Abcam), rabbit anti-PGC-1α (1:1000, Abcam), rabbit anti-Nrf2 (1:1000, Abcam), rabbit anti-interleukin (IL) -1β (1:1000, Abcam), rabbit anti-interleukin (IL) -6 (1:1000, Abcam), mouse anti-TNF-α(1:500, Abcam) and mouse anti-β-actin(1:3000, Santa Cruz). The next day, the anti-rabbit (or anti-mouse) secondary antibodies (1:3000, Santa Cruz Biotechnology, USA) were incubated at room temperature for 1-2 h. The gray values were quantified and analyzed by Image J software (NIH).

Histological analysis

Rats were deeply anesthetized and perfused with cold PBS solution followed by 4% formaldehyde solution through the heart at 48h or 28d post HIE. The brains were isolated and post-fixed with 10% formalin (24h) then transferred into 20% sucrose solution, followed by 30% sucrose solution for dehydration. The brains were sliced into 10mm slices for immunofluorescence staining, or 20 mm for Nissl’s staining.

Immunofluorescence staining

Immunofluorescence staining was conducted as described previously[36]. The 10mm-thick brain slices were incubated with rabbit anti-GPR39 (1:50, Bioss), rabbit anti-interleukin (IL) -1β (1:100, Abcam), mouse anti-myeloperoxidase (MPO) (1:100, Abcam). The second day, the brain slices were incubated with the appropriate fluorescence-conjugated secondary antibodies (1:200) in the dark at room temperature. The stained sections were then visualized with a fluorescence microscope (Leica DMI8, Leica Microsystems, Germany), and photomicrographs of double-fluorescence labeling were merged to observe the expression of GPR39 on oligodendrocytes, and the staining positive cells of IL-1β and MPO were counted.

Nissl staining

The 20mm-thick brain slices were immersed in the following solutions, 95% ethanol for 2 minute, 70% ethanol for 2 minute, distilled water for 30s, 0.5% cresyl violet (Sigma-Aldrich, USA) for 2 min, distilled water for 30s, 100% ethanol and xylene for 1.5 min twice. Subsequently, the brain slices were mounted with DPX (Sigma-Aldrich, USA). The image of the brain slice was obtained by microscope (Olympus BX51) equipped with MagnaFire SP 2.1B. Brain tissue loss was calculated with Image J software (NIH) and 3 brain slices in each brain were included in the analysis. The percentage of brain tissue loss = [(contralateral hemisphere - ipsilateral hemisphere)/contralateral hemisphere] × 100%[37, 38].
Results

1. Time course expression levels of endogenous GPR39, SIRT1, PGC-1α and Nrf2 post HIE

The endogenous expression levels of GPR39 receptor and pathway-related protein SIRT1, PGC-1α and Nrf2 were measured at six time points post HIE. Compared with the sham group, GPR39, SIRT1, PGC-1α and Nrf2 were markedly increased from 12h to 72h and peaked at 24 h or 48h post HIE (Fig.1).

2. TC-G 1008 treatment reduced the percent infarcted area and improved short-term neurological function at 48h post HIE

To investigate the neuroprotective effects of TC-G1008 treatment, three doses, low (5mg/kg), medium (15mg/kg), and high (45mg/kg), were tested. From the TTC results, low and medium doses of TC-G 1008 showed to significantly reduce the percent infarcted area compared to vehicle group (Fig.2A, B). The high dose group did not show significant improvement compared to the vehicle group. In addition, medium dose of TC-G 1008 significantly reduced HIE-induced body weight loss of rat pups (Fig.2E). Negative geotaxis test showed that medium dose of TC-G 1008 significantly relieved neurological deficits caused by hypoxia ischemia (Fig.2C). However, same effect of TC-G 1008 treatment was not observed in the righting reflex (Fig.2D). In our experiment, no unusual behavior was observed in pups post administration of TC-G1008. Thus, these results implied that 15mg/kg of TC-G1008 showed a more effective neuroprotective effect and was selected for further experiments.

3. Immunofluorescence staining showed the colocalization of GPR39 with microglia at 48 h post HIE

Double immunofluorescence staining of GPR39 receptor and Iba-1 (a marker for microglia) was carried out in the sham, vehicle and TC-G 1008 treatment group at 48h post HIE. As shown in Fig.3, GPR39 was colocalized with microglia and the expression level of GPR39 on microglia was up-regulated in the vehicle group when compared with the sham group. Moreover, TC-G 1008 treatment further enhanced the expression of GPR39 on microglia.

4. TC-G 1008 improved long-term neurological function and reduced brain atrophy at 4 weeks post HIE

Foot-fault, rotarod and water maze tests were performed to evaluate the effects of TC-G 1008 treatment on the long-term neurological functions post HIE.

In the water maze test, compared with the control group, vehicle-treated animals were observed to spend more time and swim longer distances to find the platform, and less time in the platform quadrant. However, TC-G 1008 treatment relieved cognitive impairment, and improved memory and learning abilities compared with vehicle animals, as showed by the significantly shorter time it took for rats to find the platform (Fig. 4B), shorter swimming distance (Fig. 4A), and more time spent in the platform quadrant (Fig. 4C).
Vehicle animals performed markedly worse compared with sham animals in foot-fault test, and TC-G 1008 treatment group showed to significantly reduce the total foot-faults and contralateral foot-faults when compared with the rats in the vehicle group (Fig. 4F). Furthermore, TC-G 1008 treatment significantly increased the falling latency at both 5 rpm and 10 rpm acceleration compared to vehicle in rotarod test (Fig. 4G).

The brain atrophy was evaluated by nissl staining at 4 weeks post-HIE. The vehicle group displayed severe brain damage caused by HIE, characterized by brain tissue loss in ipsilateral hemisphere. It was significantly attenuated post TC-G 1008 treatment when compared with vehicle group (Fig. 4E,H).

5. In vivo inhibition of GPR39, SIRT1 and PGC-1α abolished TC-G 1008’s neuroprotective effects at 48 h post HIE

To analyze whether GPR39 receptor and signaling pathway related proteins, SIRT1 and PGC-1α, were involved in the neuroprotective effects of TC-G 1008, we inhibited GPR39 and PGC-1α using CRISPR, and SIRT1 with EX527.

GPR39 CRISPR®PGC-1α CRISPR and EX527 reversed the protective effects of TC-G 1008, as shown from the significant increase in the percent infarcted area when compared to the corresponding control groups(Fig. 5A,B). Negative geotaxis and righting reflex tests showed that rat pups treated with TC-G 1008 in combination with either GPR39 CRISPR, PGC-1α CRISPR or SIRT1 inhibitor EX527 had markedly impaired neurological function compared with corresponding controls (Fig. 5C,D). Consistently, inhibition of GPR39®PGC-1α and SIRT1 abolished the effect of TC-G 1008 and significantly changed the weight of the animals when compared with corresponding treatment control groups (Fig. 5E).

Moreover, Animal groups treated with GPR39 CRISPR or PGC-1α CRISPR, or EX527 have significantly higher intensity levels of MPO and IL-1β than corresponding treatment control groups at 48h post HIE (Fig.6).

6. In vivo inhibition of GPR39, SIRT1 and PGC-1α abolished the anti-neuroinflammatory effect of TC-G1008 through the GPR39/SIRT1/PGC-1α/Nrf2 signaling pathway at 48 h post HIE.

Western blot data (Fig.7A) showed that GPR39 receptor and pathway related proteins SIRT1, PGC-1α, Nrf2, and pivotal inflammatory cytokines IL-6, IL-1β, TNF-α were up-regulated in vehicle group when compared with sham. TC-G 1008 treatment further increased the expression levels of GPR39, SIRT1, PGC-1α and Nrf2, but decreased the expression levels of IL-6, IL-1β and TNF-α when compared with vehicle group. Inhibition of GPR39 significantly decreased GPR39 expression, thereby abolishing the neuroprotective effects of TC-G 1008, resulting in a decrease in SIRT1, PGC-1α and Nrf2 expression, and an increase in IL-6, IL-1β and TNF-α expression.

In order to further explore the role of signaling pathway proteins in the anti-neuroinflammatory effect of TC-G 1008, SIRT1 inhibitor EX527 and PGC-1α CRISPR were used.
The results showed that EX527 abolished the effects of TC-G 1008, resulting in a decrease in PGC-1α and Nrf2 expression, and an increase in IL-6, IL-1β and TNF-α expression. Similarly, PGC-1α CRISPR significantly decreased PGC-1α expression, thereby abolishing the effects of TC-G 1008, resulting in a decrease in Nrf2 expression, and an increase in IL-6, IL-1β and TNF-α expression.

The trend of the western blot results of inflammatory factors was consistent with the findings of our immunofluorescence staining of IL-1β and MPO.

**Discussion**

In this study we aimed at evaluating the anti-inflammatory effects and the potential underlying mechanisms of GPR39 in a rat model of neonatal HIE. Our findings demonstrated that (1) the expression of GPR39 and pathway-related proteins, SIRT1–PGC-1α and Nrf2 were increased in a time-dependent manner, peaking at 24 h or 48h post HIE. (2) GPR39 was expressed in microglia at 48h post HIE. (3) Intranasal administration of TC-G 1008 (15mg/kg) reduced the percent infarcted area and improved short-term and long-term neurological deficits. (4) TC-G 1008 attenuated neuroinflammation in part via the SIRT1/PGC-1α/Nrf2 pathway in a rat model of neonatal HIE.

In the central nervous system (CNS), it has been previously demonstrated that high GPR39 mRNA levels are present in the amygdala, hippocampus, and auditory cortex[15], with Zn^{2+} identified as the “physiological agonist” of GPR39 [39]. Extracellular Zn^{2+} activates ZnR/GPR39 receptor, thereby triggering multiple signaling pathways including, G_αs and G_αq/PLC/IP3[40]. Previous studies indicated that a zinc-deficient diet led to the decreased expression of GPR39, and Zinc supplementation for 4 weeks, significantly abolished the abnormal expression of GPR39 in the hippocampus[41]. Previous studies have reported that post ischemia, neurons massively release extracellular Zn^{2+} to promote the production of pro-inflammatory cytokines[42]. In this study, we demonstrated that the expression of GPR39 was increased in a time-dependent manner post HIE. Thus, the release of Zn^{2+} from neurons post HIE may have led to the up-regulation of GPR39 expression that we observed.

As a specific agonist of GPR39, TC-G 1008 is widely used to explore the effect of GPR39 activation[25, 43, 44]. Previous studies have shown that treatment with TC-G 1008 (100 nM and 1 μM) enhanced keratinocyte proliferation through an ERK-dependent pathway[45]. Furthermore, TC-G 1008-mediated GPR39 activation promoted osteoblast differentiation and mineralization[43]. In a study where they investigated the effect of GPR39 on the intestinal barrier function, treatment with TC-G 1008 (1 μM -10 μM) enhanced tight junction assembly in intestinal epithelial cells by PLC-CaMKKβ-AMPK pathways[46]. The expression of GPR39 in the hippocampus and hippocampal cells (HT-22) was upregulated following administration of TC-G 1008[21, 28]. Advanced glycation end products reduced GPR39 expression in a dose-dependent manner and TC-G 1008 reversed the effects of AGEs [47]. In this study, GPR39 was upregulated post TC-G 1008 administration as seen from our immunofluorescence staining and mechanism studies, which is consistent with previous studies.
GPR39 plays an important role in wound healing, depression, inflammatory bowel diseases, alcohol use disorder, insulin secretion and several cancers [23, 46, 48-52]. However, the neuroprotective function of GPR39 has been partially confirmed. Studies have shown that GPR39 overexpression protected cells from undergoing cell death in a hippocampal cell line, and revealed its underlying mechanisms involving apoptosis and endoplasmic reticulum stress[29]. In another study, GPR39 exhibited its neuroprotective role by inhibiting apoptosis and thus protecting hippocampal neurons (HT-22) from corticosterone-induced injury[28]. Furthermore, it was observed that the zinc diet-treated group increased the expression of GPR39 and BMP protein, and improved cognitive impairment, while it showed to decrease hippocampal mossy fiber regenerative sprouting[41]. Therefore, GPR39 has been proposed as a potential therapeutic target for ischemia/reperfusion injury and neurodegenerative diseases[29]. In the present study, low and medium dose of TC-G 1008 showed to significantly reduce the percent infarcted area compared to vehicle group (Fig.2A, B). In addition, medium dose of TC-G 1008 significantly reduced HIE induced body weight loss of rat pups (Fig.2E). As shown in rats’ performance in the water maze, foot-fault, and rotarod test, TC-G 1008 improved long-term neurological function (Fig.4). In general, activation of GPR39 with TC-G 1008 reduced the percent infarcted area and improved short-term and long-term neurological deficits.

Although the underlying mechanism is not completely understood, inflammation is one of the main contributors to the pathogenic cascade post HIE. Hypoxia-ischemia initiates the inflammatory reaction in the brain parenchyma and the peripheral immune system, which mediates secondary brain injury and can last for a few days[7, 8]. Therefore, new agents that target inflammation will open new avenues for therapy of neonatal hypoxic–ischemic brain injury. GPR39, a recently discovered zinc-sensing receptor, has been proven to have anti-inflammatory effects in several studies[25-27, 53, 54].

GPR39 mediates synovial inflammation by ameliorating the expression of pro-inflammatory cytokines such as IL-β and IL-6[25]. In the process of GPR39 regulating the activity of endothelial cells, Zn+ is involved in the regulation of some inflammation-related key molecules including heme oxygenase-1, selectin L and IL-10[53]. GPR39 was upregulated in thioglycollate-induced peritoneal macrophages and exerted its anti-inflammatory effects by increasing the production of IL-10[27]. It has been shown that treatment with TC-G 1008 abolished the increased expression of pro-inflammatory cytokines induced by ox-LDL in the prevention of atherosclerosis[26]. However, in the process of promoting wound healing, the activation of GPR39 has the effect of promoting inflammation by increasing the production of pro-inflammatory cytokines IL-6[54]. In the present study, we first discovered its anti-inflammatory effect in the brain by reducing the production of IL-6, IL-1β and TNF-α, as showed from the result of immunofluorescence staining of MPO and IL-1β and western blotting (Fig.6-9).

Numerous studies have shown that activation of SIRT1 is a neuroprotective agent for ischemic stroke through several mechanisms[55-58]. TC-G 1008 treatment mitigated IL-1b-induced inhibition of SIRT1, and the effect of TC-G 1008 on p53 acetylation and chondrocyte senescence were abrogated when SIRT1 was silenced[44]. Previous studies have indicated that PGC-1α was a major regulator of ROS metabolism and mitochondria biogenesis which closely related to the pathology of ischemic diseases and
Several studies focusing on ischemic injury implied that the expression and activity of PGC1-α are at least partially dependent on SIRT1. Icariin has a neuroprotective effect in mice subjected to post MCAO via increasing the SIRT1 and PGC-1α expression [60]. Ghrelin significantly attenuates brain damage post HIE via the GHSR-1α/AMPK/Sirt1/PGC-1α/UCP2 signaling pathway[61]. Activation of the PGC-1α/Nrf-2/HO-1 signaling pathway plays a critical role in tannic acid (TA) administration against traumatic brain injury through reducing oxidative damage, mitochondrial impairment, and inflammation[62]. In addition, the expression levels of SIRT1 PGC1-a and Nrf2 were significantly up-regulated post HIE[61, 63], which is consistent with the results observed in our study. The activation of GPR39 increased the expression of SIRT1, PGC-1α and Nrf2, and reduced the expression of pro-inflammatory cytokines ADD FIGURE #, but this effect was reversed by GPR39 CRISPR. EX527 and PGC-1α CRISPR abolished the effects of TC-G 1008, resulting in a decrease in PGC-1α and Nrf2 expression, and an increase in IL-6, IL-1β and TNF-α expression. Similar effects have also been observed in our immunofluorescence staining experiments of IL-1β and MPO. Therefore, the anti-inflammatory effect of GPR39 is partly dependent on the SIRT1/PGC-1α/Nrf2 signaling pathway post HIE. The role of other neuroprotective functions and underlying mechanisms will need to be further investigated.

**Conclusions**

In conclusion, intranasal administration of TC-G 1008 reduced the percent infarcted area and improved short-term and long-term neurological deficits post HIE. TC-G 1008 attenuated neuroinflammation in part via the SIRT1/PGC-1α/Nrf2 pathway in a rat model of neonatal HIE. TC-G 1008 may be a novel therapeutic target for treatment post neonatal HIE injury. Activating GPR39 may be a promising therapeutic target to attenuate neuroinflammation post neonatal HIE.

**Abbreviations**

CCA: common carotid; CNS: central nervous system; GPR39: G protein-coupled receptor 39; HIE: Hypoxic-ischemic encephalopathy; MPO: myeloperoxidase; Nrf2: nuclear factor, erythroid 2 like 2; PGC-1α: peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α); ROS: reactive oxygen species; SIRT1: sirtuin 1; TA: tannic acid.

**Declarations**

**Acknowledgements**

Not applicable

**Ethical approval and consent to participate**

All experimental protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Loma Linda University, which comply with the National Institutes of Health Guidelines for the Care and Use of
Laboratory Animals in Neuroscience Research and ARRIVE guidelines.

Authors’ contributions

This study was designed by SCX, DMD, JPT, and JHZ. The experiments were completed by SCX, HS, PJ, LG, RL, XH, and JX. SCX, XIJ, and LNZ performed the statistical analysis. SCX, XLJ, and LNZ finished writing the manuscript. LNZ, JPT and JHZ provided supervision and final check. All the authors read the final version of this paper and approved it.

Funding

This study was supported by grants from the National Institutes of Health (NS104083) to John H. Zhang, and a grant from Key Research and Development Project of Hainan Province (ZDYF2019147) to Shucai Xie.

Availability of data and materials

The data support the findings of this study and are available from the corresponding author upon reasonable request.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interest.

References

1. Adstamongkonkul D, Hess DC: Ischemic Conditioning and neonatal hypoxic ischemic encephalopathy: a literature review. Cond Med 2017, 1:9-16.

2. Greco P, Nencini G, Piva I, Scioscia M, Volta CA, Spadaro S, Neri M, Bonaccorsi G, Greco F, Cocco I, et al: Pathophysiology of hypoxic-ischemic encephalopathy: a review of the past and a view on the future. Acta Neurol Belg 2020, 120:277-288.

3. Altamentova S, Rumajogee P, Hong J, Beldick SR, Park SJ, Yee A, Fehlings MG: Methylprednisolone Reduces Persistent Post-ischemic Inflammation in a Rat Hypoxia-Ischemia Model of Perinatal Stroke. Transl Stroke Res 2020, 11:1117-1136.

4. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, et al: Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010, 375:1969-1987.
5. Douglas-Escobar M, Weiss MD: Hypoxic-ischemic encephalopathy: a review for the clinician. *JAMA Pediatr* 2015, 169:397-403.

6. Higgins RD, Raju T, Edwards AD, Azzopardi DV, Bose CL, Clark RH, Ferriero DM, Guillet R, Gunn AJ, Hagberg H, et al: Hypothermia and other treatment options for neonatal encephalopathy: an executive summary of the Eunice Kennedy Shriver NICHD workshop. *J Pediatr* 2011, 159:851-858 e851.

7. Algra SO, Groeneveld KM, Schadenberg AW, Haas F, Evens FC, Meerding J, Koenderman L, Jansen NJ, Prakken BJ: Cerebral ischemia initiates an immediate innate immune response in neonates during cardiac surgery. *J Neuroinflammation* 2013, 10:24.

8. Wang LW, Chang YC, Lin CY, Hong JS, Huang CC: Low-dose lipopolysaccharide selectively sensitizes hypoxic ischemia-induced white matter injury in the immature brain. *Pediatr Res* 2010, 68:41-47.

9. Iadecola C, Anrather J: The immunology of stroke: from mechanisms to translation. *Nat Med* 2011, 17:796-808.

10. Hagberg H, Mallard C, Ferriero DM, Vannucci SJ, Levison SW, Vexler ZS, Gressens P: The role of inflammation in perinatal brain injury. *Nat Rev Neurol* 2015, 11:192-208.

11. Bhalala US, Koehler RC, Kannan S: Neuroinflammation and neuroimmune dysregulation after acute hypoxic-ischemic injury of developing brain. *Front Pediatr* 2014, 2:144.

12. Lyu J, Jiang X, Leak RK, Shi Y, Hu X, Chen J: Microglial Responses to Brain Injury and Disease: Functional Diversity and New Opportunities. *Transl Stroke Res* 2021, 12:474-495.

13. McKee KK, Tan CP, Palyha OC, Liu J, Feighner SD, Hreniuk DL, Smith RG, Howard AD, Van der Ploeg LH: Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors. *Genomics* 1997, 46:426-434.

14. Egerod KL, Holst B, Petersen PS, Hansen JB, Mulder J, Hokfelt T, Schwartz TW: GPR39 splice variants versus antisense gene LYPD1: expression and regulation in gastrointestinal tract, endocrine pancreas, liver, and white adipose tissue. *Mol Endocrinol* 2007, 21:1685-1698.

15. Jackson VR, Nothacker HP, Civelli O: GPR39 receptor expression in the mouse brain. *Neuroreport* 2006, 17:813-816.

16. Hershfinkel M: The Zinc Sensing Receptor, ZnR/GPR39, in Health and Disease. *Int J Mol Sci* 2018, 19.

17. Zhao H, Qiao J, Zhang S, Zhang H, Lei X, Wang X, Deng Z, Ning L, Cao Y, Guo Y, et al: GPR39 marks specific cells within the sebaceous gland and contributes to skin wound healing. *Sci Rep* 2015,
18. Sunuwar L, Medini M, Cohen L, Sekler I, Hershfinkel M: The zinc sensing receptor, ZnR/GPR39, triggers metabotropic calcium signalling in colonicocytes and regulates occludin recovery in experimental colitis. *Philos Trans R Soc Lond B Biol Sci* 2016, 371.

19. Gilad D, Shorer S, Ketzef M, Friedman A, Sekler I, Aizenman E, Hershfinkel M: Homeostatic regulation of KCC2 activity by the zinc receptor mZnR/GPR39 during seizures. *Neurobiol Dis* 2015, 81:4-13.

20. Ding Q, Li H, Tian X, Shen Z, Wang X, Mo F, Huang J, Shen H: Zinc and imipramine reverse the depression-like behavior in mice induced by chronic restraint stress. *J Affect Disord* 2016, 197:100-106.

21. Mlyniec K, Starowicz G, Gawel M, Frackiewicz E, Nowak G: Potential antidepressant-like properties of the TC G-1008, a GPR39 (zinc receptor) agonist. *J Affect Disord* 2016, 201:179-184.

22. Moran BM, Abdel-Wahab YH, Vasu S, Flatt PR, McKillop AM: GPR39 receptors and actions of trace metals on pancreatic beta cell function and glucose homoeostasis. *Acta Diabetol* 2016, 53:279-293.

23. Jiang Y, Li T, Wu Y, Xu H, Xie C, Dong Y, Zhong L, Wang Z, Zhao H, Zhou Y, et al: GPR39 Overexpression in OSCC Promotes YAP-Sustained Malignant Progression. *J Dent Res* 2020, 99:949-958.

24. Mero M, Asraf H, Sekler I, Taylor KM, Hershfinkel M: Corrigendum to "ZnR/GPR39 upregulation of K(+)/Cl(-)-cotransporter 3 in tamoxifen resistant breast cancer cells" [Cell Calcium 81 (2019) 12-20]. *Cell Calcium* 2019, 83:102077.

25. Jing W, Sun W, Zhang N, Zhao C, Yan X: The protective effects of the GPR39 agonist TC-G 1008 against TNF-alpha-induced inflammation in human fibroblast-like synoviocytes (FLSs). *Eur J Pharmacol* 2019, 865:172663.

26. Xu Y, Wang M, Xie Y, Jiang Y, Liu M, Yu S, Wang B, Liu Q: Activation of GPR39 with the agonist TC-G 1008 ameliorates ox-LDL-induced attachment of monocytes to endothelial cells. *Eur J Pharmacol* 2019, 858:172451.

27. Muneoka S, Goto M, Kadoshima-Yamaoka K, Kamei R, Terakawa M, Tomimori Y: G protein-coupled receptor 39 plays an anti-inflammatory role by enhancing IL-10 production from macrophages under inflammatory conditions. *Eur J Pharmacol* 2018, 834:240-245.

28. Mo F, Tang Y, Du P, Shen Z, Yang J, Cai M, Zhang Y, Li H, Shen H: GPR39 protects against corticosterone-induced neuronal injury in hippocampal cells through the CREB-BDNF signaling pathway. *J Affect Disord* 2020, 272:474-484.

29. Dittmer S, Sahin M, Pantlen A, Saxena A, Toutzaris D, Pina AL, Geerts A, Golz S, Methner A: The constitutively active orphan G-protein-coupled receptor GPR39 protects from cell death by increasing
secretion of pigment epithelium-derived growth factor. *J Biol Chem* 2008, 283:7074-7081.

30. Sanchez-Temprano A, Relova JL, Camina JP, Pazos Y: Concurrent Akt, ERK1/2 and AMPK Activation by Obestatin Inhibits Apoptotic Signaling Cascades on Nutrient-Deprived PC12 Cells. *Cell Mol Neurobiol* 2021.

31. Rice JE, 3rd, Vannucci RC, Brierley JB: The influence of immaturity on hypoxic-ischemic brain damage in the rat. *Ann Neurol* 1981, 9:131-141.

32. Lioutas VA, Alfaro-Martinez F, Bedoya F, Chung CC, Pimentel DA, Novak V: Intranasal Insulin and Insulin-Like Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke. *Transl Stroke Res* 2015, 6:264-275.

33. Hu X, Li S, Doycheva DM, Huang L, Lenahan C, Liu R, Huang J, Xie S, Tang J, Zuo G, Zhang JH: Rh-CSF1 attenuates neuroinflammation via the CSF1R/PLCG2/PKCepsilon pathway in a rat model of neonatal HIE. *J Neuroinflammation* 2020, 17:182.

34. Griemert EV, Recarte Pelz K, Engelhard K, Schafer MK, Thal SC: PAI-1 but Not PAI-2 Gene Deficiency Attenuates Ischemic Brain Injury After Experimental Stroke. *Transl Stroke Res* 2019, 10:372-380.

35. Tulsulkar J, Glueck B, Hinds TD, Jr., Shah ZA: Ginkgo biloba Extract Prevents Female Mice from Ischemic Brain Damage and the Mechanism Is Independent of the HO1/Wnt Pathway. *Transl Stroke Res* 2016, 7:120-131.

36. Zhang Y, Zhang X, Wei Q, Leng S, Li C, Han B, Bai Y, Zhang H, Yao H: Activation of Sigma-1 Receptor Enhanced Pericyte Survival via the Interplay Between Apoptosis and Autophagy: Implications for Blood-Brain Barrier Integrity in Stroke. *Transl Stroke Res* 2020, 11:267-287.

37. Zhang Y, Ding Y, Lu T, Zhang Y, Xu N, Yu L, McBride DW, Flores JJ, Tang J, Zhang JH: Bliverdin reductase-A improves neurological function in a germinal matrix hemorrhage rat model. *Neurobiol Dis* 2018, 110:122-132.

38. Zhang Y, Xu N, Ding Y, Doycheva DM, Zhang Y, Li Q, Flores J, Haghghiabyaneh M, Tang J, Zhang JH: Chemerin reverses neurological impairments and ameliorates neuronal apoptosis through ChemR23/CAMKK2/AMPK pathway in neonatal hypoxic-ischemic encephalopathy. *Cell Death Dis* 2019, 10:97.

39. Depoortere I: GI functions of GPR39: novel biology. *Curr Opin Pharmacol* 2012, 12:647-652.

40. Rychlik M, Mlyniec K: Zinc-mediated Neurotransmission in Alzheimer's Disease: A Potential Role of the GPR39 in Dementia. *Curr Neuropharmacol* 2020, 18:2-13.
41. Chen NN, Zhao DJ, Sun YX, Wang DD, Ni H: Long-Term Effects of Zinc Deficiency and Zinc Supplementation on Developmental Seizure-Induced Brain Damage and the Underlying GPR39/ZnT-3 and MBP Expression in the Hippocampus. *Front Neurosci* 2019, 13:920.

42. Higashi Y, Aratake T, Shimizu S, Shimizu T, Saito M: [Brain zinc dyshomeostasis and glial cells in ischemic stroke]. *Nihon Yakurigaku Zasshi* 2019, 154:138-142.

43. Chai X, Zhang W, Chang B, Feng X, Song J, Li L, Yu C, Zhao J, Si H: GPR39 agonist TC-G 1008 promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. *Artif Cells Nanomed Biotechnol* 2019, 47:3569-3576.

44. Lu H, Wang D, Li H, Zhong J, Lin Y, Xu X, Wang B: GPR39 agonist TC-G 1008 ameliorates IL-1beta-induced chondrocyte senescence. *Artif Cells Nanomed Biotechnol* 2019, 47:2612-2617.

45. Satianrapapong W, Pongkorpsakol P, Muanprasat C: A G-protein coupled receptor 39 agonist stimulates proliferation of keratinocytes via an ERK-dependent pathway. *Biomed Pharmacother* 2020, 127:110160.

46. Pongkorpsakol P, Buasakdi C, Chantivas T, Chatsudthipong V, Muanprasat C: An agonist of a zinc-sensing receptor GPR39 enhances tight junction assembly in intestinal epithelial cells via an AMPK-dependent mechanism. *Eur J Pharmacol* 2019, 842:306-313.

47. Shan W, Qi J, Li C, Nie X: Agonism of GPR39 displays protective effects against advanced glycation end-product (AGE)-induced degradation of extracellular matrix in human SW1353 cells. *Arch Biochem Biophys* 2019, 677:108164.

48. Cuzon Carlson VC, Ford MM, Carlson TL, Lomniczi A, Grant KA, Ferguson B, Cervera-Juanes RP: Modulation of Gpr39, a G-protein coupled receptor associated with alcohol use in non-human primates, curbs ethanol intake in mice. *Neuropsychopharmacology* 2019, 44:1103-1113.

49. Starowicz G, Jarosz M, Frackiewicz E, Grzechnik N, Ostachowicz B, Nowak G, Mlyniec K: Long-lasting antidepressant-like activity of the GPR39 zinc receptor agonist TC-G 1008. *J Affect Disord* 2019, 245:325-334.

50. Mero M, Asraf H, Sekler I, Taylor KM, Hershfinkel M: ZnR/GPR39 upregulation of K(+)/Cl(-)-cotransporter 3 in tamoxifen resistant breast cancer cells. *Cell Calcium* 2019, 81:12-20.

51. Xie F, Liu H, Zhu YH, Qin YR, Dai Y, Zeng T, Chen L, Nie C, Tang H, Li Y, et al: Overexpression of GPR39 contributes to malignant development of human esophageal squamous cell carcinoma. *BMC Cancer* 2011, 11:86.

52. Fjellstrom O, Larsson N, Yasuda S, Tsuchida T, Oguma T, Marley A, Wennberg-Huldt C, Hovdal D, Fukuda H, Yoneyama Y, et al: Novel Zn2+ Modulated GPR39 Receptor Agonists Do Not Drive Acute Insulin Secretion in Rodents. *PLoS One* 2015, 10:e0145849.
53. Zhu D, Su Y, Zheng Y, Fu B, Tang L, Qin YX: Zinc regulates vascular endothelial cell activity through zinc-sensing receptor ZnR/GPR39. *Am J Physiol Cell Physiol* 2018, 314:C404-C414.

54. Nishida K, Hasegawa A, Yamasaki S, Uchida R, Ohashi W, Kurashima Y, Kunisawa J, Kimura S, Iwanaga T, Watarai H, et al: Mast cells play role in wound healing through the ZnT2/GPR39/IL-6 axis. *Sci Rep* 2019, 9:10842.

55. Zhang JF, Zhang YL, Wu YC: The Role of Sirt1 in Ischemic Stroke: Pathogenesis and Therapeutic Strategies. *Front Neurosci* 2018, 12:833.

56. Chen M, Wang Z, Zhou W, Lu C, Ji T, Yang W, Jin Z, Tian Y, Lei W, Wu S, et al: SIRT1/PGC-1alpha signaling activation by mangiferin attenuates cerebral hypoxia/reoxygenation injury in neuroblastoma cells. *Eur J Pharmacol* 2021, 907:174236.

57. Luo Y, Chen H, Tsoi B, Wang Q, Shen J: Danggui-Shaoyao-San (DSS) Ameliorates Cerebral Ischemia-Reperfusion Injury via Activating SIRT1 Signaling and Inhibiting NADPH Oxidases. *Front Pharmacol* 2021, 12:653795.

58. Zhou F, Wang YK, Zhang CG, Wu BY: miR-19a/b-3p promotes inflammation during cerebral ischemia/reperfusion injury via SIRT1/FoxO3/SPHK1 pathway. *J Neuroinflammation* 2021, 18:122.

59. Chen SD, Yang DI, Lin TK, Shaw FZ, Liou CW, Chuang YC: Roles of oxidative stress, apoptosis, PGC-1alpha and mitochondrial biogenesis in cerebral ischemia. *Int J Mol Sci* 2011, 12:7199-7215.

60. Zhu HR, Wang ZY, Zhu XL, Wu XX, Li EG, Xu Y: Icariin protects against brain injury by enhancing SIRT1-dependent PGC-1alpha expression in experimental stroke. *Neuropharmacology* 2010, 59:70-76.

61. Huang J, Liu W, Doycheva DM, Gamdzyk M, Lu W, Tang J, Zhang JH: Ghrelin attenuates oxidative stress and neuronal apoptosis via GHSR-1alpha/AMPK/Sirt1/PGC-1alpha/UCP2 pathway in a rat model of neonatal HIE. *Free Radic Biol Med* 2019, 141:322-337.

62. Salman M, Tabassum H, Parvez S: Tannic Acid Provides Neuroprotective Effects Against Traumatic Brain Injury Through the PGC-1alpha/Nrf2/HO-1 Pathway. *Mol Neurobiol* 2020, 57:2870-2885.

63. Gao Y, Fu R, Wang J, Yang X, Wen L, Feng J: Resveratrol mitigates the oxidative stress mediated by hypoxic-ischemic brain injury in neonatal rats via Nrf2/HO-1 pathway. *Pharm Biol* 2018, 56:440-449.

**Figures**
Figure 1

Temporal expression of GPR39/SIRT1/PGC-1α/Nrf2 in the brain post HIE. (A) A representative western blot bands of the time course. (B-E) The endogenous expression levels of GPR39, SIRT1, PGC-1α and Nrf2 were increased from 12h to 72h, and peaked at 24 h or 48h post HIE. (Data are represented as mean ± SD; *p < 0.05 vs. sham, n = 6/group).
Figure 2

Effect of intranasal administration of TC-G 1008 on brain infarct area, short-term neurological function and body weight at 48 h post HIE. (A-B) TTC staining showed that low (5mg/kg) and medium (15 mg/kg) doses of TC-G 1008 significantly reduced infarct area when compared with vehicle. (C–D) Righting reflex and Geotaxis reflex showed that middle dose (15 mg/kg) of TC-G 1008 significantly improved neurological function compared to vehicle animals. (E) TC-G 1008 significantly reduced HIE induced body weight loss of rat pups. (Data are represented as mean ± SD; *p < 0.05 vs. sham; #p < 0.05 vs. HIE + vehicle, n = 6/group).
Figure 3

Representative immunofluorescence staining of GPR39 and the microglia marker Iba-1 in the brain at 48 h post HIE. GPR39 was co-localized with Iba-1 in the sham (A), vehicle (B), and TC-G 1008 treatment (30 mg/kg) group (C) respectively. Compared with the sham group, GPR39 (green) expression was increased on microglia (red) in vehicle group and further increased post TC-G 1008 treatment. Blue was for nucleus (DAPI). (D) Quantitative analysis of GPR39-positive Iba-1 cells in the ipsilateral cortex at 48 h post HIE. (E) The schematic diagram shows the location of immunofluorescence staining (small white box). (Data are represented as mean ± SD; *p < 0.05 vs. sham; #p < 0.05 vs. HIE + vehicle; n = 4/group; Scale bar = 50 μm).
Effects of TC-G 1008 treatment on neurological function and brain atrophy at 4 weeks post HIE. TC-G 1008 treatment group showed significant improvement in spatial memory loss as shown by shorter swimming distance (A), decrease in escape latency (B), and more time spent in the target quadrant during the probe trial (C,D). TC-G 1008 treatment significantly improved motor function as shown by foot-fault test (F) and rotarod test (G). TC-G 1008 treatment significantly reduced the percent of tissue loss (E,H) when compared with the vehicle.
Figure 5

Effects of GPR39 and PGC-1α CRISPR, and SIRT1 inhibitor EX527 with TC-G 1008 on infarct volume, neurological function and body weight at 48 hours post HIE. (A, B) Animal groups treated with GPR39 CRISPR or PGC-1α CRISPR, or EX527 have significant greater proportion of infarction when compared with respective controls treated with TC-G 1008. (C, D) Animal groups treated with GPR39 CRISPR or PGC-1α CRISPR, or EX527 significantly abolished the neurological benefit of TC-G 1008 when compared with respective controls. (E) TC-G 1008 treatment or TC-G 1008 with DMSO significantly attenuated HIE induced body weight loss, which were reversed by GPR39 CRISPR or PGC-1α CRISPR, or EX527. \( \ast p < 0.05 \) vs. sham; \( \# p < 0.05 \) vs. HIE+vehicle; \( \mathring{\circ} p < 0.05 \) vs. HIE+TC-G1008+control CRISPR; \( \mathring{\ast} p < 0.05 \) vs. HIE+TC-G1008+DMSO. \( n = 6 \) for each group.
Figure 6

Effects of GPR39 and PGC-1α CRISPR, and SIRT1 inhibitor EX527 with TC-G 1008 on immunofluorescence staining of MPO and IL-1β at 48 h post HIE. TC-G 1008 treatment or TC-G 1008 with DMSO significantly reduced the number of IL-1β/MPO-positive cells, which were abolished by either GPR39 CRISPR or PGC-1α CRISPR, or EX527. *p < 0.05 vs. sham; #p < 0.05 vs. HIE+vehicle; @p < 0.05 vs. HIE+TC-G1008+control CRISPR; $p < 0.05 vs. HIE+TC-G1008+DMSO. n = 4 for each group.
Figure 7

GPR39 CRISPR abolished anti-inflammatory effects of TC-G 1008 via GPR39/SIRT1/PGC-1α/Nrf2 signaling pathway at 48 h post HIE. (A) Representative western blot bands. (B-H) Densitometric quantification of GPR39, SIRT1, PGC-1α, Nrf2, IL-1β, IL-6 and TNF-α in the ipsilateral hemisphere showed that TC-G 1008 treatment further upregulated the levels of GPR39, SIRT1, PGC-1α, and Nrf2, leading to less pro-inflammatory cytokines of IL-1β and TNF-α. GPR39 CRISPR significantly abolished such effects when administered with TC-G 1008. *p < 0.05 vs. sham; #p < 0.05 vs. HIE+vehicle; @p < 0.05 vs. HIE+TC-G1008+control CRISPR. Data are represented as mean ± SD, n = 6 for each group.
SIRT1 inhibitor EX527 abolished the anti-inflammatory effects of TC-G 1008 via GPR39/SIRT1/PGC-1α/Nrf2 signaling pathway at 48 h post HIE. (A) Representative western blot bands. (B-H) Densitometric quantification of GPR39, SIRT1, PGC-1α, Nrf2, IL-1β, IL-6 and TNF-α in the ipsilateral hemisphere showed that EX527 significantly abolished the effects of TC-G 1008 treatment, resulting in a decrease in PGC-1α and Nrf2 expression, and an increase in IL-6, IL-1β and TNF-α expression. *p<0.05 vs. sham; #p <0.05 vs. HIE+vehicle; @p <0.05 vs. HIE+TC-G1008+control CRISPR, Data are represented as mean ± SD, n = 6 for each group.
Figure 9

PGC-1α abolished the anti-inflammatory effects of TC-G 1008 via GPR39/SIRT1/PGC-1α/Nrf2 signaling pathway at 48 h post HIE. (A) Representative western blot bands. (B-H) Densitometric quantification of GPR39, SIRT1, PGC-1α, Nrf2, IL-1β, IL-6 and TNF-α in the ipsilateral hemisphere showed that PGC-1α significantly abolished the effects of TC-G 1008 treatment, resulting in a decrease in Nrf2 expression, and an increase in IL-6, IL-1β and TNF-α expression.*p<0.05 vs. sham; #p <0.05 vs. HIE+vehicle; $p < 0.05 vs. HIE+TC-G1008+DMSO, Data are represented as mean ± SD, n = 6 for each group.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Fig.S1animalused.png